Tags : Involvement

Merck’s Keytruda (pembrolizumab) Receives FDA’s Approval for Adjuvant Treatment of

Shots: The approval is based on P-III EORTC1325/KEYNOTE-054 trial results assessing Keytruda (pembrolizumab,200mg, q3w) vs PBO in 1019 patients in the ratio (1:1) with completely resected stage IIIA, IIIB or IIIC melanoma for 1yr or until disease recurrence or unacceptable toxicity P-III EORTC1325/KEYNOTE-054 trial results: 43% reduction in the risk of disease recurrence or death; […]Read More